

External Quality Assessment Scheme

***Borrelia burgdorferi* antibodies** **Round 1, 2023**

Specimens

Please find enclosed 2 human plasma samples S001 and S002, each 0.5 mL.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations

BorrAb
BorrAbG
BorrAbM
Clinical interpretation

Storage and use

The specimens should be stored at 2 ... 8 °C and analysed as soon as possible, preferably within a week. Analyse as adult patient samples.

Result reporting

Please enter the results and methods via LabScala. If you can't find your instrument or reagent from the registry, please contact the EQA Coordinator.

S001:



S002:



2023-01-16

INSTRUCTIONS

Product no. 5960
LQ757323011-012/FI

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **February 7, 2023**.

The expected results of the round are published in LabScala in the View Reports section by February 13, 2023.

Inquiries

EQA Coordinator
Satu Eklund
satu.eklund@labquality.fi

Labquality

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com




Client report

	No of participants	No of responded participants	Response percentage
Borrelia burgdorferi, antibodies, European origin, January, 1-2023	66	64	97 %

Summary

Overall success rate by samples




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	8	8	100 %	1.7 %	98.3 %
Sample S002	8	8	100 %	2.5 %	97.5 %
Average:			100 %	2.1 %	97.9 %

History	Test nr.	Own success rate	Difference	AVR success rate
History not found				


Sample S001

Sample S001 success rate



Sample S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	1.5 %	98.5 %	83
	BorrAb	-	-	-	-	100 %	5
	BorrAbG	2	2	100 %	2.5 %	97.5 %	80
	BorrAbM	2	2	100 %	1.4 %	98.6 %	70
	Total:	8	8	100 %	1.7 %	98.3 %	238


Sample S001 Clinical interpretation



Bordeline, follow-up sample requested
 Sign of past or on-going infection
 Positive, referred for confirmation
 Our laboratory does not give a clinical interpretation to the physician


Clinical interpretation	Interpretation	Interpretation count	Own score	Max score	Own success rate	Difference	AVR success rate
	Bordeline, follow-up sample requested	1	-	-	-	-	0 %
	Sign of past or on-going infection	33	-	-	-	-	100 %
	<input checked="" type="radio"/> Positive, referred for confirmation	34	4	4	100 %	0 %	100 %
	Our laboratory does not give a clinical interpretation to the physician	15	-	-	-	-	-
	Total:	83	4	4	100 %	1.5 %	98.5 %

Sample S001 BorrAb




Positive

Sample S001 BorrAbG



Negative Borderline Positive

Sample S001 BorrAbM



Borderline Positive

BorrAb	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		5		-				100 %
		Immunitics C6-LYME-ELISA		3					
		Reagent C6 LYME IgM/IgG EIA		1					
		Reagent ReaScan+ LYME IgM/IgG Combo		1					
	Total:		5		-	-	-	-	100 %

OWN DEVICE: LIAISON 2

BorrAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		TestLine SmartEIA Borrelia recombinant IgG		1					
	Borderline		1		-				0 %
		In-house IFA		1					
	<input checked="" type="radio"/> Positive		78		2	2	100 %	0 %	100 %
		Aesku Diagn AESKULISA Borrelia IgG ELISA		1					
		Biomedica Borrelia IgG ELISA Recomb.		1					
		bioMérieux VIDAS Lyme IgG		13					
		<input checked="" type="radio"/> Diasorin LIAISON Borrelia IgG		35					
		Euroimmun Anti-Borrelia plus VlsE Elisa IgG		2					
		Euroimmun Anti-Borrelia Select ELISA IgG		1					
		Euroimmun Westernblot/ EUROLINE-WB IgG		6					
		Mikrogen Line Blot Recomb IgG		2					
		Mikrogen recomBead Borrelia IgG		1					
		Orgentec Borrelia IgG Recomb.		2					
		Reagent ReaScan+ C6 LYME IgG		1					
		Testline BLOT-LINE Borrelia HGA IgG		1					
		TestLine CLIA Borrelia recombinant IgG		1					
		Testline EIA Borrelia recombinant IgG		2					
		TestLine Microblot-Array Borrelia IgG		2					
		Thermo Scientific IDEIA Borrelia Burgdorferi IgG		1					
		Viramed Borrelia ViraStripe IgG		2					
		Vircell VirClia Borrelia IgG		1					
		Virion/Serion Borrelia burgdorferi IgG ELISA classic		1					
		Virotech Borrelia afzelii + VlsE IgG Europe ELISA		1					
		Virotech Borrelia Europe plus Tpn17 LINE IgG		1					


Total:		80	2	2	100 %	2.5 %	97.5 %
--------	--	----	---	---	-------	-------	--------

OWN DEVICE: LIAISON 2

BorrAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Borderline		1		-				0 %
		In-house IFA		1					
	<input checked="" type="radio"/> Positive		69		2	2	100 %	0 %	100 %
		Aesku Diagn AESKULISA Borrelia IgM ELISA		1					
		Biomedica Borrelia IgM ELISA Recomb.		1					
		bioMérieux VIDAS Lyme IgM		12					
		<input checked="" type="radio"/> Diasorin LIAISON Borrelia IgM		30					
		Euroimmun Anti-Borrelia ELISA IgM		1					
		Euroimmun Lyme screen ELISA IgM		2					
		Euroimmun Westernblot/ EUROLINE-WB IgM		6					
		Mikrogen Line Blot Recomblot IgM		2					
		Mikrogen recomBead Borrelia IgM		1					
		Orgentec Borrelia IgM Recomb.		1					
		Testline BLOT-LINE Borrelia HGA IgM		1					
		TestLine CLIA Borrelia recombinant IgM		1					
		Testline EIA Borrelia recombinant IgM		2					
		TestLine Microblot-Array Borrelia IgM		2					
		TestLine SmartEIA Borrelia recombinant IgM		1					
		Viramed Borrelia ViraStripe IgM		1					
		Vircell VirClia Borrelia IgM		1					
		Virion/Serion Borrelia burgdorferi IgM ELISA classic		1					
		Virotech Borrelia afzelii IgM ELISA		1					
		Virotech Borrelia Europe LINE IgM Line Immunoblot		1					
	Total:		70		2	2	100 %	1.4 %	98.6 %


Sample S002

Sample S002 success rate



Sample S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	4.7 %	95.3 %	83
	BorrAb	-	-	-	-	100 %	5
	BorrAbG	2	2	100 %	0 %	100 %	80
	BorrAbM	2	2	100 %	1.4 %	98.6 %	71
	Total:	8	8	100 %	2.5 %	97.5 %	239


Sample S002 Clinical interpretation



Negative, no evidence of infection
 Bordeline, follow-up sample requested
 Sign of past or on-going infection
 Positive, referred for confirmation
 Our laboratory does not give a clinical interpretation to the physician


Clinical interpretation	Interpretation	Interpretation count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative, no evidence of infection	3	-				0 %
	Bordeline, follow-up sample requested	5	-				100 %
	Sign of past or on-going infection	21	-				100 %
	<input checked="" type="radio"/> Positive, referred for confirmation	35	4	4	100 %	0 %	100 %
	Our laboratory does not give a clinical interpretation to the physician	19	-				-
	Total:	83	4	4	100 %	4.7 %	95.3 %

Sample S002 BorrAb




Positive

Sample S002 BorrAbG



Negative Borderline Positive

Sample S002 BorrAbM



Borderline Positive

BorrAb	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		5		-				100 %
		Immunitics C6-LYME-ELISA		3					
		Reagent C6 LYME IgM/IgG EIA		1					
		Reagent ReaScan+ LYME IgM/IgG Combo		1					
	Total:		5		-	-	-	-	100 %

OWN DEVICE: LIAISON 2

BorrAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		59		2	2	100 %	0 %	100 %
		Biomedica Borrelia IgG ELISA Recomb.		1					
		bioMérieux VIDAS Lyme IgG		13					
		<input checked="" type="radio"/> Diasorin LIAISON Borrelia IgG		33					
		Euroimmun Anti-Borrelia plus VlsE Elisa IgG		1					
		Euroimmun Anti-Borrelia Select ELISA IgG		1					
		Euroimmun Westernblot/ EUROLINE-WB IgG		2					
		In-house IFA		1					
		Mikrogen Line Blot Recomb. IgG		2					
		Orgentec Borrelia IgG Recomb.		1					
		Testline BLOT-LINE Borrelia HGA IgG		1					
		TestLine SmartEIA Borrelia recombinant IgG		1					
		Thermo Scientific IDEIA Borrelia Burgdorferi IgG		1					
		Viramed Borrelia ViraStripe IgG		1					
	Borderline		11		-				100 %
		Diasorin LIAISON Borrelia IgG		2					
		Euroimmun Anti-Borrelia plus VlsE Elisa IgG		1					
		Mikrogen recomBead Borrelia IgG		1					
		Orgentec Borrelia IgG Recomb.		1					
		TestLine CLIA Borrelia recombinant IgG		1					
		TestLine Microblot-Array Borrelia IgG		2					
		Viramed Borrelia ViraStripe IgG		1					
		Virotech Borrelia afzelii + VlsE IgG Europe ELISA		1					
		Virotech Borrelia Europe plus Tpn17 LINE IgG		1					
	Positive		10		-				100 %
		Aesku Diagn AESKULISA Borrelia IgG ELISA		1					

	Euroimmun Westernblot/ EUROLINE-WB IgG		4						
	Reagent ReaScan+ C6 LYME IgG		1						
	Testline EIA Borrelia recombinant IgG		2						
	Vircell VirClia Borrelia IgG		1						
	Virion/Serion Borrelia burgdorferi IgG ELISA classic		1						
	Total:		80		2	2	100 %	0 %	100 %

OWN DEVICE: LIAISON 2

BorrAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Borderline		1		-				0 %
		Virotech Borrelia Europe LINE IgM Line Immunoblot		1					
	<input checked="" type="radio"/> Positive		70		2	2	100 %	0 %	100 %
		Aesku Diagn AESKULISA Borrelia IgM ELISA		1					
		Biomedica Borrelia IgM ELISA Recomb.		1					
		bioMérieux VIDAS Lyme IgM		12					
		<input checked="" type="radio"/> Diasorin LIAISON Borrelia IgM		30					
		Euroimmun Anti-Borrelia ELISA IgM		1					
		Euroimmun Lyme screen ELISA IgM		2					
		Euroimmun Westernblot/ EUROLINE-WB IgM		6					
		In-house IFA		1					
		Mikrogen Line Blot Recomblot IgM		2					
		Mikrogen recomBead Borrelia IgM		1					
		Orgentec Borrelia IgM Recomb.		1					
		Testline BLOT-LINE Borrelia HGA IgM		1					
		TestLine CLIA Borrelia recombinant IgM		1					
		Testline EIA Borrelia recombinant IgM		2					
		TestLine Microblot-Array Borrelia IgM		2					
		TestLine SmartEIA Borrelia recombinant IgM		1					
		Viramed Borrelia ViraStripe IgM		2					
		Vircell VirClia Borrelia IgM		1					
		Virion/Serion Borrelia burgdorferi IgM ELISA classic		1					
		Virotech Borrelia afzelii IgM ELISA		1					
	Total:		71		2	2	100 %	1.4 %	98.6 %

Report Info

PARTICIPANTS

Altogether 66 laboratories from 16 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.


The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Borrelia burgdorferi, antibodies, European origin, January, 1-2023	66	64	97 %

Summary


Overall success rate by samples



Summary	AVR success rate
Sample S001	98.3 %
Sample S002	97.5 %
Average:	97.9 %


Sample S001

Sample S001 success rate



Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	98.5 %	83
	BorrAb	100 %	5
	BorrAbG	97.5 %	80
	BorrAbM	98.6 %	70
	Total:	98.3 %	238


Sample S001 Clinical interpretation



Bordeline, follow-up sample requested
 Sign of past or on-going infection
 Positive, referred for confirmation
 Our laboratory does not give a clinical interpretation to the physician


Clinical interpretation	Interpretation	Interpretation count	AVR success rate	Interpretation Score
	Bordeline, follow-up sample requested	1	0 %	0
	Sign of past or on-going infection	33	100 %	4
	Positive, referred for confirmation	34	100 %	4
	Our laboratory does not give a clinical interpretation to the physician	15	-	-
	Total:	83	98.5 %	

Sample S001 BorrAb




Positive

Sample S001 BorrAbG



Negative Borderline Positive

Sample S001 BorrAbM



Borderline Positive

BorrAb	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		5		100 %	2
		Immunitics C6-LYME-ELISA		3		
		Reagent C6 LYME IgM/IgG EIA		1		
		Reagent ReaScan+ LYME IgM/IgG Combo		1		
	Total:		5		100 %	


BorrAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		1		0 %	0
		TestLine SmartEIA Borrelia recombinant IgG		1		
	Borderline		1		0 %	0
		In-house IFA		1		
	Positive		78		100 %	2
		Aesku Diagn AESKULISA Borrelia IgG ELISA		1		
		Biomedica Borrelia IgG ELISA Recomb.		1		
		bioMérieux VIDAS Lyme IgG		13		
		Diasorin LIAISON Borrelia IgG		35		
		Euroimmun Anti-Borrelia plus VlsE Elisa IgG		2		
		Euroimmun Anti-Borrelia Select ELISA IgG		1		
		Euroimmun Westernblot/ EUROLINE-WB IgG		6		
		Mikrogen Line Blot Recomb. IgG		2		
		Mikrogen recomBead Borrelia IgG		1		
		Orgentec Borrelia IgG Recomb.		2		
		Reagent ReaScan+ C6 LYME IgG		1		
		Testline BLOT-LINE Borrelia HGA IgG		1		
		TestLine CLIA Borrelia recombinant IgG		1		
		Testline EIA Borrelia recombinant IgG		2		
		TestLine Microblot-Array Borrelia IgG		2		
		Thermo Scientific IDEIA Borrelia Burgdorferi IgG		1		
		Viramed Borrelia ViraStripe IgG		2		
		Vircell VirClia Borrelia IgG		1		
		Virion/Serion Borrelia burgdorferi IgG ELISA classic		1		
		Virotech Borrelia afzelii + VlsE IgG Europe ELISA		1		
		Virotech Borrelia Europe plus TpN17 LINE IgG		1		
	Total:		80		97.5 %	

BorrAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Borderline		1		0 %	0
		In-house IFA		1		
	Positive		69		100 %	2
		Aesku Diagn AESKULISA Borrelia IgM ELISA		1		
		Biomedica Borrelia IgM ELISA Recomb.		1		
		bioMérieux VIDAS Lyme IgM		12		

	Diasorin LIAISON Borrelia IgM		30		
	Euroimmun Anti-Borrelia ELISA IgM		1		
	Euroimmun Lyme screen ELISA IgM		2		
	Euroimmun Westernblot/ EUROLINE-WB IgM		6		
	Mikrogen Line Blot Recomblot IgM		2		
	Mikrogen recomBead Borrelia IgM		1		
	Orgentec Borrelia IgM Recomb.		1		
	Testline BLOT-LINE Borrelia HGA IgM		1		
	TestLine CLIA Borrelia recombinant IgM		1		
	Testline EIA Borrelia recombinant IgM		2		
	TestLine Microblot-Array Borrelia IgM		2		
	TestLine SmartEIA Borrelia recombinant IgM		1		
	Viramed Borrelia ViraStripe IgM		1		
	Vircell VirClia Borrelia IgM		1		
	Virion/Serion Borrelia burgdorferi IgM ELISA classic		1		
	Virotech Borrelia afzelii IgM ELISA		1		
	Virotech Borrelia Europe LINE IgM Line Immunoblot		1		
	Total:		70		98.6 %


Sample S002

Sample S002 success rate



Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	95.3 %	83
	BorrAb	100 %	5
	BorrAbG	100 %	80
	BorrAbM	98.6 %	71
	Total:	97.5 %	239


Sample S002 Clinical interpretation



Negative, no evidence of infection
 Bordeline, follow-up sample requested
 Sign of past or on-going infection
 Positive, referred for confirmation
 Our laboratory does not give a clinical interpretation to the physician


Clinical interpretation	Interpretation	Interpretation count	AVR success rate	Interpretation Score
	Negative, no evidence of infection	3	0 %	0
	Bordeline, follow-up sample requested	5	100 %	4
	Sign of past or on-going infection	21	100 %	4
	Positive, referred for confirmation	35	100 %	4
	Our laboratory does not give a clinical interpretation to the physician	19	-	-
	Total:	83	95.3 %	

Sample S002 BorrAb




Positive

Sample S002 BorrAbG



Negative Borderline Positive

Sample S002 BorrAbM



Borderline Positive

BorrAb	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		5		100 %	2
		Immunitics C6-LYME-ELISA		3		
		Reagent C6 LYME IgM/IgG EIA		1		
		Reagent ReaScan+ LYME IgM/IgG Combo		1		
	Total:		5		100 %	

BorrAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		59		100 %	2
		Biomedica Borrelia IgG ELISA Recomb.		1		
		bioMérieux VIDAS Lyme IgG		13		
		Diasorin LIAISON Borrelia IgG		33		
		Euroimmun Anti-Borrelia plus VlsE Elisa IgG		1		
		Euroimmun Anti-Borrelia Select ELISA IgG		1		
		Euroimmun Westernblot/ EUROLINE-WB IgG		2		
		In-house IFA		1		
		Mikrogen Line Blot Recomblot IgG		2		
		Orgentec Borrelia IgG Recomb.		1		
		Testline BLOT-LINE Borrelia HGA IgG		1		
		TestLine SmartEIA Borrelia recombinant IgG		1		
		Thermo Scientific IDEIA Borrelia Burgdorferi IgG		1		
		Viramed Borrelia ViraStripe IgG		1		
	Borderline		11		100 %	2
		Diasorin LIAISON Borrelia IgG		2		
		Euroimmun Anti-Borrelia plus VlsE Elisa IgG		1		
		Mikrogen recomBead Borrelia IgG		1		
		Orgentec Borrelia IgG Recomb.		1		
		TestLine CLIA Borrelia recombinant IgG		1		
		TestLine Microblot-Array Borrelia IgG		2		
		Viramed Borrelia ViraStripe IgG		1		
		Virotech Borrelia afzelii + VlsE IgG Europe ELISA		1		
		Virotech Borrelia Europe plus TpN17 LINE IgG		1		
	Positive		10		100 %	2
		Aesku Diagn AESKULISA Borrelia IgG ELISA		1		
		Euroimmun Westernblot/ EUROLINE-WB IgG		4		
		Reagent ReaScan+ C6 LYME IgG		1		
		Testline EIA Borrelia recombinant IgG		2		
		Viricell VirClia Borrelia IgG		1		
		Virion/Serion Borrelia burgdorferi IgG ELISA classic		1		
	Total:		80		100 %	

BorrAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Borderline		1		0 %	0

		Virotech Borrelia Europe LINE IgM Line Immunoblot		1		
	Positive		70		100 %	2
		Aesku Diagn AESKULISA Borrelia IgM ELISA		1		
		Biomedica Borrelia IgM ELISA Recomb.		1		
		bioMérieux VIDAS Lyme IgM		12		
		Diasorin LIAISON Borrelia IgM		30		
		Euroimmun Anti-Borrelia ELISA IgM		1		
		Euroimmun Lyme screen ELISA IgM		2		
		Euroimmun Westernblot/ EUROLINE-WB IgM		6		
		In-house IFA		1		
		Mikrogen Line Blot Recomblot IgM		2		
		Mikrogen recomBead Borrelia IgM		1		
		Orgentec Borrelia IgM Recomb.		1		
		Testline BLOT-LINE Borrelia HGA IgM		1		
		TestLine CLIA Borrelia recombinant IgM		1		
		Testline EIA Borrelia recombinant IgM		2		
		TestLine Microblot-Array Borrelia IgM		2		
		TestLine SmartEIA Borrelia recombinant IgM		1		
		Viramed Borrelia ViraStripe IgM		2		
		Vircell VirClia Borrelia IgM		1		
		Virion/Serion Borrelia burgdorferi IgM ELISA classic		1		
		Virotech Borrelia afzelii IgM ELISA		1		
	Total:		71		98.6 %	

Report Info

PARTICIPANTS

Altogether 66 laboratories from 16 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

External Quality Assessment Scheme

***Borrelia burgdorferi*, antibodies** **Round 1, 2023**

Specimens

In this round, there were two authentic plasma samples, each originating from a single human donor. The homogeneity of samples was ensured during the sample preparation. The antibodies are known to be stable and there are no special requirements for their handling or storage. The samples were suitable for the external quality assessment scheme. The materials were sent without temperature control packaging.

The accepted results were as follows:

Sample S001 (LQ757323011)

BorrAb	Positive
BorrAbG	Positive
BorrAbM	Positive
Clinical interpretation	Sign of past or on-going infection Positive, referred for confirmation

Sample S002 (LQ757323012)

BorrAb	Positive
BorrAbG	Negative/Borderline/Positive
BorrAbM	Positive
Clinical interpretation	Sign of past or on-going infection Positive, referred for confirmation Borderline, follow-up sample requested

Report info

It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – Expert

In the first round of the year, the samples were borrelia antibody positive. These samples have been previously as EQA samples in the same order in the third round in 2020, and in the fourth round in 2021.

Sample S001 was IgG and IgM borrelia antibody positive. IgG antibodies recognized the VlsE antigen, and IgM antibodies were directed mainly to OspC. All but one of the participating laboratories reported positive IgM results, and also IgG antibodies were positive in the analyses of most laboratories (78/80). The accepted clinical interpretations of the sample were “Sign of past or on-going infection” or “Positive, referred for confirmation”.

Sample S002 was positive in IgM antibodies with only one false borderline result. In IgG borrelia antibodies, 59 negative, 11 borderline, and ten positive IgG results were reported. The assays used by the expert laboratory indicated the presence of low levels of IgG antibodies against VlsE. Therefore, all IgG results were accepted and scored 2 points. IgM antibodies reacted mainly against OspC. The accepted clinical interpretations of the sample were “Sign of past or on-going infection”, “Positive referred for confirmation”, and “Borderline, follow-up sample requested”

End of report

Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.

2023-02-15

FINAL REPORT

Product no. 5960

Subcontracting: Sample pretesting

Samples sent	2023-01-16
Round closed	2023-02-07
Final report	2023-02-15

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Satu Eklund
satu.eklund@labquality.fi

Expert

Dr. Jukka Hytönen, MD, PhD
University of Turku and
Turku University Hospital
Turku, Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

info@labquality.fi

www.labquality.com

